TY - JOUR
T1 - Ventilatory Impairments Associated with Parkinson's Disease
T2 - A Systematic Review and Meta-Analysis
AU - López-López, Laura
AU - Rodríguez-Torres, Janet Remedios
AU - Cahalin, Lawrence Patrick
AU - Cabrera-Martos, Irene
AU - Torres Sánchez, Irene
AU - Valenza, Marie Carmen
N1 - Funding Information:
This work was financed jointly by the Fundación Progreso y Salud and Boehringer Ingelheim España SA (Project code: PI-0370-2014), Oximesa, Praxair. The author J.R.R.-T. has received financial support through an FPU (Formación Profesorado Uni-versitario) grant (FPU: 16/01531) of the Spanish Ministry of Education. The author L.L.L.-L. has received financial support through an FPU grant (FPU: 17/00408) of the Spanish Ministry of Education (Spain).
Publisher Copyright:
© 2021 S. Karger AG, Basel. All rights reserved.
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/2
Y1 - 2021/2
N2 - Background: The peripheral and central repercussions of Parkinson's disease (PD) affect the neuromuscular system producing a loss of muscle strength that can influence the respiratory system. Although several studies have examined various respiratory aspects of PD, to the best of our knowledge no study to date has systematically reviewed the existing data. Objectives: To examine the available literature related to the respiratory impairment in PD patients. Methods: We used PRISMA guidelines when reporting this review. We searched Pubmed, Cinhal, SciELO, and Cochrane Library, from inception until August 2018. Main variables assessed were forced vital capacity percent predicted (FVC%) and forced expiratory volume in 1 s percent predicted (FEV1%) for PD patients. Results: Six studies were included in this systematic review and meta-analysis. The obtained results concluded that PD patients present poorer pulmonary function when compared to healthy controls. When PD patients were compared between ON and OFF states, the results reviewed are in favour of the ON state. In the meta-analysis performed for FVC% and FEV1%, the results fail to find significant differences between PD patients and controls (p = 0.336 and p = 0.281, respectively), and between PD ON and OFF states (p = 0.109 and p = 0.059, respectively). Conclusions: We conclude that PD patients have impaired respiratory capacities that are related to the PD severity, time since diagnosis, and OFF state. Adequate follow-up of the respiratory function and studies focused on PD phenotypes have to be considered in future studies.
AB - Background: The peripheral and central repercussions of Parkinson's disease (PD) affect the neuromuscular system producing a loss of muscle strength that can influence the respiratory system. Although several studies have examined various respiratory aspects of PD, to the best of our knowledge no study to date has systematically reviewed the existing data. Objectives: To examine the available literature related to the respiratory impairment in PD patients. Methods: We used PRISMA guidelines when reporting this review. We searched Pubmed, Cinhal, SciELO, and Cochrane Library, from inception until August 2018. Main variables assessed were forced vital capacity percent predicted (FVC%) and forced expiratory volume in 1 s percent predicted (FEV1%) for PD patients. Results: Six studies were included in this systematic review and meta-analysis. The obtained results concluded that PD patients present poorer pulmonary function when compared to healthy controls. When PD patients were compared between ON and OFF states, the results reviewed are in favour of the ON state. In the meta-analysis performed for FVC% and FEV1%, the results fail to find significant differences between PD patients and controls (p = 0.336 and p = 0.281, respectively), and between PD ON and OFF states (p = 0.109 and p = 0.059, respectively). Conclusions: We conclude that PD patients have impaired respiratory capacities that are related to the PD severity, time since diagnosis, and OFF state. Adequate follow-up of the respiratory function and studies focused on PD phenotypes have to be considered in future studies.
KW - Levodopa
KW - Parkinson's disease
KW - Pulmonary function
UR - http://www.scopus.com/inward/record.url?scp=85100054245&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85100054245&partnerID=8YFLogxK
U2 - 10.1159/000506234
DO - 10.1159/000506234
M3 - Article
C2 - 33472204
AN - SCOPUS:85100054245
VL - 100
SP - 173
EP - 181
JO - Respiration; international review of thoracic diseases
JF - Respiration; international review of thoracic diseases
SN - 0025-7931
IS - 2
ER -